期刊文献+

慢性阻塞性肺疾病与肺外相关疾病的研究进展 被引量:9

Research Progress in COPD and Extrapulmonary Related Diseases
在线阅读 下载PDF
导出
摘要 慢性阻塞性肺疾病(COPD)是一种以气流受限不完全可逆为特征的可以预防和治疗的疾病,主要累及肺脏,但也可以引起全身(或肺外)的不良反应。2009年版GOLD(慢性阻塞性肺疾病全球倡议)强调每例患者临床病情取决于症状严重程度、全身效应和各种合并症,而并非仅仅与气流受限程度相关。对COPD的阐述更注重肺外效应与患者疾病严重程度的相关性,在COPD的临床管理中也更关注对其肺外效应和合并症的处理。 Chronic obstructive pulmonary disease (COPD)is a disease characterized by less reversible airflow limitation,which can be prevented and treated. COPD mainly involves the lungs, but can also cause systemic (extrapuhnonary) adverse reactions. The 2009 GOLD ( Global Initiative for Chronic Obstructive Pul- monary Disease) stressed that the individual clinical condition depends on the severity of symptoms, systemic effect and variety of complications, not only the degree of airflow limitation. More emphasis is on the correla- tion of the disease and extrapulmonary effect, while in the clinical management of COPD, there are also more concerns about the treatment of extrapulmonary effects and pulmonary complications.
出处 《医学综述》 2012年第19期3220-3222,共3页 Medical Recapitulate
关键词 慢性阻塞性肺疾病 肺外效应 合并症 Chronic obstructive pulmonary disease Extrapulmonary effects Complications
  • 相关文献

参考文献21

  • 1Testelmans D,Crul T,Maes K,et al.Atrophy and hypertrophy sig-nalling in the diaphragm of patients with COPD[J].Eur Respir J,2010,35(3):549-556.
  • 2Plant PJ,Brooks D,Faughnan M,et al.Cellular markers of muscleatrophy in chronic obstructive pulmonary disease[J].Am J RespirCell Mol Biol,2010,42(4):461-467.
  • 3Hayot M,Rodriguez J,Vernus B,et al.Myostatin up-regulation isassociated with the skeletal muscle response to hypoxic stimuli[J].Mol Cell Endocrinol,2011,332(1/2):38-47.
  • 4Calverley PM,Anderson JA,Celli B,et al.Cardiovascular events inpatients with COPD:TORCH study results[J].Thorax,2010,65(8):719-725.
  • 5Nussbaumer-Ochsner Y,Rabe KF.Systemic manifestations ofCOPD[J].Chest,2011,139(1):165-173.
  • 6Rutten FH,Zuith off NP,Hak E,et al.Beta-blockers may reducemortality and risk of exacerbations in patients with chronic obstruc-tive pulmonary disease[J].Arch Intern Med,2010,170(10):880-887.
  • 7Young RP,Hopkins RJ.Possible role of statins in COPD-relatedpulmonary hypertension[J].Chest,2010,137(5):1250-1251.
  • 8Blanchette CM,Berry SR,Lane SJ.Advances in chronic obstructivepulmonary disease among older adults[J].Curr Opin Pulm Med,2011,17(2):84-89.
  • 9van Gestel YR,Hoeks SE,Sin DD,et al.COPD and cancer mortali-ty:the influence of statins[J].Thorax,2009,64(11):963-967.
  • 10Chakrabarti B,Angus RM,Agarwal S,et al.Hyperglycaemia as apredictor of outcome during non-invasive ventilation in decompen-sated COPD[J].Thorax,2009,64(10):857-862.

二级参考文献91

  • 1柳涛,蔡柏蔷.一种新型的生活质量评估问卷:慢性阻塞性肺疾病评估测试[J].中国医学科学院学报,2010,32(2):234-238. 被引量:165
  • 2慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8245
  • 3中华人民共和国卫生部.WS 318-2010慢性阻塞性肺疾病诊断标准.北京:中国标准出版社,2010.
  • 4Karayama M,Inui N,Suda T,et al.Antiendothelial cell antibodies in patients with COPD.Chest,2010,138:1303-1308.
  • 5Han MK,Agusti A,Calverley PM.et al.Chronic obstructive pulmonary disease phenotypes:the future of COPD.Am J Respir Crit Care Med,2010,182:598-604.
  • 6Burgel PR,Paillasseur JL,Caillaud D,et al.Clinical COPD phenotypes:a novel approach using principal component and cluster analyses.Eur Respir J,2010,36:531-539.
  • 7Guntupalli KK,Gutterman D,Raoof S,et al.2010:the year of the lung.Chest 2010,138:1287-1288.
  • 8Brito-Mutunayagam R,Appleton SL,Wilson DH,et al.GlobalInitiative for Chronic Obstructive Lung Disease stage 0 is associated with excess FEV (1) decline in a representative population sample.Chest,2010,138:605-613.
  • 9张富强 郑劲平 王佳泓 等.支气管舒张试验的容量和流量反应评估慢性阻塞性肺疾病比较[J].中华结核和呼吸杂志,2010,.
  • 10Hannink JD,van Helvoort HA,Dekhuijzen PN,et al.Dynamic hyperinflation during daily activities.Does COPD Global Initiative for Chronic Obstructive Lung Disease stage matter? Chest,2010,137:1116-1121.

共引文献107

同被引文献67

引证文献9

二级引证文献69

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部